## Biosynthetic PEG-MAL Hydrogel Stimulates Angiogenic Sprouting in Mouse Aortic Rings

Rutwik Rath<sup>1</sup>, Edward A. Phelps<sup>2</sup> Andrés J. García<sup>2</sup>


<sup>1</sup>Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta GA
<sup>2</sup>Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta GA

Statement of Purpose: Diabetes mellitus produces abnormalities of angiogenesis that may cause or contribute to many of the clinical manifestations of diabetes<sup>1</sup>. As vascularization is an essential design goal for successful cell-based therapies, we developed an in vitro model to study angiogenesis. In our research, we are studying vascular-inductive (in vivo) polyethylene glycol maleimide (PEG-MAL) hydrogel as a supportive islet delivery matrix for angiogenic therapies in type I diabetes and chronic limb ischemia<sup>2</sup>. We characterized the 3D spreading and migration behavior of encapsulated cells and tissue sections in PEG-MAL hydrogel towards development of an in vitro angiogenic analysis assay. While the majority of published research using PEGdiacrylate and PEG-vinyl sulfone matrices evaluate angiogenesis in vitro with 10% or higher (wt/vol) hydrogel<sup>3</sup>, we notably found that a much lower wt/vol percentage hydrogel was necessary to achieve cell spreading or angiogenic sprouting in 3D in our hydrogel system.

Methods: NIH-3T3 fibroblast cells were embedded in matrigel and 5% and 2.5% (wt/vol) hydrogels to determine a wt/vol % material threshold for cell spreading and migration. Then, aortic cross sections were obtained from the thoracic aorta of healthy mice<sup>4</sup>. The aortic sections were encapsulated in either 5% or 2.5%(wt/vol) PEG-MAL hydrogels with GCRDVPMSMRGGDRCG (VPM) or GCRDGPQGIWGQKDRCG (GPQ), known fast-cleaving and slow-cleaving degradable peptides sensitive to collagenase respectively<sup>5</sup>. The gels were synthesized via a Michael reaction where the thiol on a cysteine residue of the cross-linking peptide conjugated (or PEGylated) the terminal amine on an arm of a multiarm PEG-MAL eventually linking arms of different PEG-MAL groups, resulting in a hydrogel structure<sup>6</sup>. We embedded the aortic sections in these gels and kept them in an incubator. We checked daily for sprouts.







Matrigel

5% PEG-MAL + rgd

2.5% PEG-IVIAL + rg

Figure 1. NIH-3T3 cell seeding, PEG-MAL hydrogel (24 hours)

**Results:** Fibroblast cells seeded in matrigel adhered and spread as expected. Cells in 5% PEG-MAL hydrogel gel did not spread and remained rounded. Cells in the 2.5% gels adhered and spread similar to matrigel (figure 1).

Aortic rings in matrigel (control) began to sprout 4 days after embedding. The 2.5% PEG-MAL hydrogels showed sprouting after 4 days (figure 2) while the 5% gels did not show any signs of sprouting. It was determined that VPM was the better crosslinking peptide with an average sprouting length of 262  $\mu$ M  $\pm$  50.5  $\mu$ M at day 5. GPQ had an average of 171.2  $\mu$ M  $\pm$  61.8  $\mu$ M (figure 3) at day 5.




Figure 2. Aortic endothelial sprouting in 2.5% PEG-MAL gels with VPM crosslinker at day 4.




Figure 3. Average Sprouting Data, day 5

Conclusions: We found that 2.5% PEG-MAL hydrogel cross-linked with VPM and GPQ supported cell spreading and migration in 3D. Based on these preliminary results, VPM is a better candidate peptide for the *in vitro* angiogenesis model. Future research hopes to add growth factors such as VEGF and FGF to increase the aortic angiogenic sprouting<sup>7</sup> in the hydrogels and provide a better environment to study therapies for vascularization. In particular we hope to utilize this *in vitro* assay to characterize difference in angiogenesis between diabetic and healthy tissue using aortas harvested from diabetic mice.

## **References:**

- 1. (Martinet A. Medical Research Review 2003; 23: 117-145.)
- 2. (Phelps E.A. Proc Natl Acad Sci U S A. 2010; 107:3323-8.)
- 3. (Moon JJ. Biomaterials 2010; 31:3840-7.)
- 4. (Zhu, W.-H. Angiogenesis 2002; 5: 81-86.)
- 5. (Patterson J. Biomaterials 2010; 31:7836-7845.)
- 6. (Veronese F. Biomaterials 2001; 22:405-417)
- 7. (Millauer B. Cell 1993; 72: 835-846.)

**Funding:** Georgia Tech President's Undergraduate Research Award